Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need

VXRT 10.15.2024

Full Press ReleaseSEC FilingsOur VXRT Tweets

About Gravity Analytica

Recent News

  • 01.14.2025 - Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
  • 01.14.2025 - Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial
  • 12.02.2024 - Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

Recent Filings

  • 01.21.2025 - EX-99.1 EX-99.1
  • 01.21.2025 - 8-K Current report
  • 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

SOUTH SAN FRANCISCO, Calif.,Oct. 15, 2024(GLOBE NEWSWIRE) --Vaxart, Inc.(Nasdaq: VXRT) today announced that it will present research demonstrating the potential of its norovirus oral pill vaccine candidate at IDWeek taking placeOctober 16-19, 2024, at theLos Angeles Convention CenterinLos Angeles.

With no currently approved vaccines against norovirus,Vaxartremains committed to progressing what it believes to be the most advanced norovirus vaccine candidate in clinical development that is both formulated for oral administration and designed for delivery to the gastrointestinal system. Norovirus sickens approximately 21 million people inthe United Stateseach year, including the 15% of children under age 5 who contract norovirus annually. Approximately 3 million sets of parents are forced by this virus to miss work – approximately 2.2 days on average – to care for their children. Adults ≥65 years old are at high-risk for severe symptoms and clinical outcomes including longer disease duration and death. The annual disease burden from norovirus inthe United Statesis estimated to be$10.6 billion

Presentation Information:

Title:A Phase 2 Double-Blind, Placebo-Controlled Study Showing Oral Tableted Norovirus Vaccine VXA-G1.1-NN is Immunogenic, Efficacious, and Reduces Viral Shedding Following Norovirus ChallengeSpeaker:Dr.Sean Tucker, Founder and Chief Scientific Officer ofVaxartDate:Thursday, October 17Time:3:45 p.m. PTRoom:404 AB

Title:A Phase I, Multicenter, Randomized, Double-blind, Placebo-controlled Single Dose, Dose-ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Orally Administered Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females ≥ 18 years Old and Their Breast-feeding InfantsSpeaker:Dr.Lam Nguyen, Medical Director & Head of Pharmacovigilance ofVaxartDate:Saturday, October 19, 2024Time:2:15 p.m. PTRoom:403 B

AboutVaxartVaxartis a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.Vaxartvaccines are designed to be administered using pills that can be stored and shipped without refrigeration and to eliminate the risk of needle-stick injury.Vaxartbelieves that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication.Vaxarthas filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@vaxart.com(646) 871-8481

This press release was published by a CLEAR® Verified individual.

Primary Logo

Source: Vaxart, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com